文献速递泌尿男性生殖肿瘤

局限期前列腺癌放疗后6个月前列腺特异性抗原的预后影响:随机试验的个体患者数据分析

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials.
PubMed 文献 · J Clin Oncol · 2024-03-12

该研究利用16项随机试验的个体患者数据,评估局限期前列腺癌患者完成放疗后6个月内最低前列腺特异性抗原(PSA)的预后影响。结果显示,PSA≥0.1 ng/mL与更低的无转移生存和总生存以及更高的前列腺癌特异性死亡率相关。该指标可用于患者咨询和临床试验设计。

要点

  • 放疗后6个月内PSA≥0.1 ng/mL在单纯放疗、短程ADT和长程ADT组中分别占98%、84%和77%。
  • PSA≥0.1 ng/mL与更低的無轉移生存和總生存以及更高的前列腺癌特異性死亡率相關。
  • 该预后指标可用于接受放疗±ADT患者的咨询和临床试验设计。

核心结论

  • 局限期前列腺癌患者完成放疗后6个月内PSA≥0.1 ng/mL对长期结局具有预后价值。
  • 该指标可用于接受放疗±ADT患者的咨询,以及指导评估新型全身治疗和(去)强化策略的临床试验设计。

研究设计与样本

  • 个体患者数据来自1987年至2011年间评估放疗±雄激素剥夺治疗(ADT)治疗局限期前列腺癌的16项随机试验。
  • 将完成放疗后6个月内记录的最低PSA categorized为<或≥0.1 ng/mL。
  • 主要结局为从随机分组后12个月起的无转移生存(MFS)、前列腺癌特异性死亡率(PCSM)和总生存(OS)。

主要发现

  • 分配至单纯放疗组98%(n=2,339/2,376)、放疗+短程ADT组84%(n=4,756/5,658)、放疗+长程ADT组77%(n=1,258/1,626)的患者在完成放疗后6个月内PSA≥0.1 ng/mL。
  • 在分配至放疗±ADT的患者中,PSA≥0.1 ng/mL与更低的MFS和OS以及更高的PCSM相关(单纯放疗:MFS HR 2.24 [95% CI 1.21-4.16],PCSM sHR 1.82 [0.51-6.49],OS HR 1.72 [0.97-3.05];放疗+短程ADT:MFS HR 1.27 [1.12-1.44],PCSM sHR 2.10 [1.52-2.92],OS HR 1.26 [1.11-1.44];放疗+长程ADT:MFS HR 1.58 [1.27-1.96],PCSM sHR 1.97 [1.11-3.49],OS HR 1.59 [1.27-1.99])。
  • 基于PSA<或≥0.1 ng/mL,分配至单纯放疗、放疗+短程ADT和放疗+长程ADT患者的5年MFS率分别为91% vs 79%、83% vs 76%和87% vs 74%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We sought to evaluate the prognostic impact of prostate-specific antigen (PSA) at 6 months after completion of radiotherapy (RT) in patients treated with RT alone, RT plus short-term (st; 3-6 months), and RT plus long-term (lt; 24-36 months) androgen-deprivation therapy (ADT). PATIENTS AND METHODS: Individual patient data were obtained from 16 randomized trials evaluating RT ± ADT for localized prostate cancer (PCa) between 1987 and 2011. The lowest PSA recorded within 6 months after RT completion was identified and categorized as < or ≥0.1 ng/mL. The primary outcomes were metastasis-free survival (MFS), PCa-specific mortality (PCSM), and overall survival (OS), from 12 months after random assignment. RESULTS: Ninety-eight percent (n = 2,339/2,376) of patients allocated to RT alone, 84% (n = 4,756/5,658) allocated to RT + stADT, and 77% (n = 1,258/1,626) allocated to RT + ltADT had PSA ≥0.1 ng/mL within 6 months after completing RT. PSA ≥0.1 ng/mL was associated with lower MFS and OS and higher PCSM among patients allocated to RT ± ADT (RT - MFS: hazard ratio [HR], 2.24 [95% CI, 1.21 to 4.16]; PCSM: subdistribution hazard ratio [sHR], 1.82 [0.51 to 6.49]; OS: HR, 1.72 [0.97 to 3.05]; RT + stADT - MFS: HR, 1.27 [1.12 to 1.44]; PCSM: sHR, 2.10 [1.52 to 2.92]; OS: HR, 1.26 [1.11 to 1.44]; RT + ltADT - MFS: HR, 1.58 [1.27 to 1.96]; PCSM: sHR, 1.97 [1.11 to 3.49]; OS: HR, 1.59 [1.27 to 1.99]). Five-year MFS rates among patients allocated to RT, RT + stADT, and RT + ltADT were 91% versus 79%, 83% versus 76%, and 87% versus 74%, respectively, based on PSA < or ≥0.1 ng/mL. CONCLUSION: PSA ≥0.1 ng/mL within 6 months after RT completion was prognostic for lt outcomes in patients treated with RT ± ADT for localized PCa. This can be used to counsel patients treated with RT ± ADT and in guiding clinical trial design evaluating novel systemic therapies with RT + ADT as well as (de)intensification strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kwak L, Ravi P, Armstrong JG, et al. Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials. J Clin Oncol. 2024. PMID: 38471051. doi:10.1200/JCO.23.00762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。